In Step 1 and prior to initiating the two series of VOR and HXTC combined therapies, all participants will undergo study screening where they will be required to: 1. Demonstrate a baseline measurement of the frequency of resting CD4 T cell infection ≥ 0.3 infected cells per million as determined by QVOA, as a further decrease from this low frequency of infection cannot be definitively measured given the QVOA assay threshold, and 2. Exhibit ex-vivo (Step 1) response to VOR